A set of 5×5 diallel crosses of Indian mustard along with their parents were evaluated to estimate general and specific combining ability of parents and crosses, respectively in year 2017 and 2018. Observations were recorded on various quantitative characters. Significant differences were observed for both general combining ability and specific combining ability for almost all the traits studied. The high magnitude of general combining ability (GCA) and specific combining ability (SCA) effects indicated the presence of both additive and non-additive gene interactions for the inheritance of different traits. Parents, IC-571663 and IC-317528 were exhibited to be good general combiners for seed yield per plant, as well as based on GCA and SCA effects, the high ranking crosses for yield and its component traits were IC-571649 × IC-571663, IC-571649 × IC-317528, IC-571649 x IC-338586 and IC-599679 x IC-338586.
Acute myeloid leukemia (AML) is a highly aggressive disease with high relapse and mortality rates. Recent years have shown a surge in novel therapeutic development for AML, both in clinical and preclinical stages. These developments include targeted therapies based on AML-specific molecular signatures as well as more general immune modulation and vaccination studies. In this review, we will explore the evolving arena of AML therapy and suggest some intriguing connections between immune system modulation and targeted therapy. Improved understanding of the immune system involvement in various stages of the disease and the crosstalk between immune effectors, targeted therapy, and AML cells can provide a better framework for designing the next generation of AML therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.